Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas

Published:2006 Issue:3-4 Volume:83 Page:258-263
ISSN:0028-3835
Container-title:Neuroendocrinology
language:en
Short-container-title:Neuroendocrinology

Author:

Saveanu Alexandru,Gunz Ginette,Guillen Severine,Dufour Henry,Culler Michael D.,Jaquet Philippe

Publisher

S. Karger AG

Subject

Cellular and Molecular Neuroscience,Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism

Reference23 articles.

1. Consensus statement: medical management of acromegaly

2. SOM230: A New Somatostatin Peptidomimetic with Potent Inhibitory Effects on the Growth Hormone/Insulin-Like Growth Factor-I Axis in Rats, Primates, and Dogs

3. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy

4. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatostatin and Somatostatin Receptors in Tumour Biology;International Journal of Molecular Sciences;2023-12-28

2. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors;The Journal of Clinical Endocrinology & Metabolism;2022-11-22

3. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature;Archives of Endocrinology and Metabolism;2022-05-25

4. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms;Frontiers in Endocrinology;2022-01-12

5. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling;Nature Reviews Endocrinology;2021-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3